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Abstract: Malignant pleural mesothelioma (MPM) is a highly aggressive cancer with limited
therapy options and dismal prognosis. In recent years, the role of immune cells within the tumor
microenvironment (TME) has become a major area of interest. In this review, we discuss the current
knowledge of heterogeneity in immune cell content and checkpoint expression in MPM in relation
to prognosis and prediction of treatment efficacy. Generally, immune-suppressive cells such as
M2 macrophages, myeloid-derived suppressor cells and regulatory T cells are present within the
TME, with extensive heterogeneity in cell numbers. Infiltration of effector cells such as cytotoxic
T cells, natural killer cells and T helper cells is commonly found, also with substantial patient to
patient heterogeneity. PD-L1 expression also varied greatly (16–65%). The infiltration of immune
cells in tumor and associated stroma holds key prognostic and predictive implications. As such,
there is a strong rationale for thoroughly mapping the TME to better target therapy in mesothelioma.
Researchers should be aware of the extensive possibilities that exist for a tumor to evade the cytotoxic
killing from the immune system. Therefore, no “one size fits all” treatment is likely to be found and
focus should lie on the heterogeneity of the tumors and TME.
Keywords: malignant pleural mesothelioma (MPM); tumor microenvironment (TME); heterogeneity;
immunotherapy; myeloid-derived suppressor cells (MDSCs); tumor-associated macrophages (TAMs);
tumor-infiltrating lymphocytes (TIL); regulatory T cells (Tregs)
1. Introduction
Malignant pleural mesothelioma (MPM) is a rare and highly aggressive cancer arising from
the mesothelial cells of the pleura with a median survival of 9 months. More than 70 percent of
MPM results from exposure of asbestos [1]. The only licensed treatment is palliative antifolate and
platinum combination chemotherapy which results in a moderate overall survival benefit of about
three months [2]. MPM consists of three histological variants: (1) epithelioid (~60% of mesotheliomas);
(2) sarcomatoid, characterized by spindle cell morphology (~20% of mesotheliomas); (3) biphasic,
a mixture of epithelioid and sarcomatoid characteristics (~20% of mesotheliomas) [3,4]. Currently,
accepted prognosticators include stage and histology of which sarcomatoid subtype results in the
lowest survival rates [5]. It has been demonstrated that protumor and antitumor immune responses
within the tumor and associated stroma also correlate with the clinical outcome of MPM [6,7].
This review discusses current knowledge of heterogeneity in immune cell content in MPM in relation
to prognosis and prediction of treatment efficacy.
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2. Tumor Microenvironment (TME) in Mesothelioma
The mesothelioma tumor microenvironment (TME) is a complex and heterogeneous mixture of
stromal, endothelial and immune cells. This composition differs between individuals and histologic
types, and can change upon administered anti-tumor therapies [8]. The role of immune cells within
the TME has become a major area of interest, as these immune cells are capable of influencing
tumor growth. In general, immune infiltration in tumors include natural killer (NK) cells, B and
T lymphocytes, mast cells, neutrophils, myeloid-derived suppressor cells (MDSCs), macrophages
and dendritic cells (DCs). NK cells, cytotoxic T cells, mature DCs and T helper cells are known to
be anti-tumorgenic, while others, like regulatory T cells (Tregs), type 2 macrophages, and MDSCs
suppress the immune response and therefore favor tumor growth and dissemination [9]. The TME
in mesothelioma is unique as it arises from exposure of mesothelial cells to asbestos fibers [6,8]. It is
known to be highly immunosuppressive, with higher numbers of immunosuppressive cells such as
type 2 tumor associated macrophages and Tregs [10–13].
3. Macrophages
Macrophages are specialized phagocytic cells which play a dual role in cancer depending on their
differentiation. Schematically, tumor-associated macrophages (TAMs) can be divided into classically
activated (M1) macrophages and alternatively activated (M2) macrophages. M1 macrophages have
pro-inflammatory, tissue destructive and anti-tumor activity. Whereas M2 macrophages can be seen
as pro-tumorgenic by promoting the metastatic capacity of a tumor due to production of multiple
cytokines (e.g., IL-1, IL-6, IL-10, VEGF and TGF-β). TAMs derive from circulating monocytic precursors.
In tumors, chemokines play an important role in recruitment of monocytes. Once recruited, interleukins
such as IL-4, IL-13 and IL-10 produced by tumor infiltrating lymphocytes (TILs) promote differentiation
of macrophages towards an M2 phenotype [14,15]. Certain drugs can skew M2 macrophages into
a more M1 phenotype [16,17]. Table 1 describes the antibodies and their associated immune cells.
Burt et al. performed a CD68 staining on tissue microarray of 52 MPM patients. Macrophages were
abundantly present in both epithelial (n = 34) and non-epithelial (n = 18) mesothelioma (tumor
infiltrating macrophages in percentage of tumor area (%) 25.2 ± 9.3 and 29.7 ± 10.2, p = 0.11).
The relatively high standard deviation indicates large heterogeneity in macrophage infiltration in
MPM. In seven patients, three with epithelial and four with non-epithelial MPM, flow cytometry was
performed displaying high levels of CD163 and CD206, characterizing them as M2 macrophages.
The absolute number of macrophages was associated with worse prognosis in non-epithelioid
mesothelioma after surgery, but not in epithelioid mesotheliomas [18]. Cornelissen et al. described
expression of CD68 and CD163 in tumor specimens of sixteen patients with epithelial MPM, eight of
them receiving induction chemotherapy and surgery and eight patients receiving chemotherapy only.
In both groups macrophages were abundantly present, whereby a large spreading in actual number of
macrophages was seen (surgery vs. non-surgery 211.3/0.025 cm2 ± 80.2 and 213.9/0.025 cm2 ± 100.4
p = 1.0). Most of these macrophages showed a M2 phenotype. A higher percentage of M2 macrophages
was significantly negative correlated with overall survival [19]. In lung cancer, Cornelissen et al.
described ten MPM patients with local tumor outgrowth after surgery and their matched controls
without local tumor outgrowth. Two biphasic and eighteen epithelial MPM patients were included.
Macrophage infiltration was characterized by large heterogeneity with a mean macrophage count of
202/0.025 cm2, ranging from 45 to 408/0.025 cm2. These macrophages show a M2 phenotype with a
mean count of 153/0.025 cm2 and a range of 42 to 422/0.025 cm2 [20]. Marcq et al. found macrophages
in stroma of all 54 MPM specimens, with a majority of samples having less than 50% CD68+ cells.
Numbers of stromal macrophages were positively correlated to the number of stromal Tregs (R = 0.41,
p = 0.002), suggesting that macrophages stimulate and recruit CD4+ cells by affecting the adaptive
immune response [15,21]. Schürch et al. found heavy infiltration of M2 macrophages in all 40 MPM
analyzed [22]. Table 2 summarizes the extent of macrophage infiltration found in these studies.
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Table 1. Cell surface markers and correlating immune cell type.
Surface Marker Present on
CD3 T lymphocytes
CD4 T helper cells
CD8 Cytotoxic T cells
CD11b Monocytes, macrophages, MDSCs, NK cells, eosinophils, neutrophils, basophils,dendritic cells, mast cells, CD8+ T cells, B cells
CD16 Natural killer cells, myeloid cells, monocytes, neutrophils
CD19 B cells
CD20 B cells
CD33 Myeloid cells
CD45 Leucocytes
CD45RO T effector and memory cells
CD56 Natural killer cells
CD68 Macrophages
CD163 M2 macrophages
CD206 M2 macrophages
Foxp3+CD4+CD25+ Regulatory T cells
Table 2. Infiltration of TAMs and M2 macrophages in mesothelioma.
Study n CD68+ Coefficient ofVariation (CV) * CD163+
Coefficient of
Variation (CV) *
[18] 52
25.2 ± 9.3%, (epithelial)
29.7 ± 10.2%,
(non-epithelial)
0.37, (epithelial)
0.34, (non-epithelial) n.a. *** n.a. ***
[19] 16
211.3 ** ± 80.2, (surgery)
213.9 ** ± 100.4,
(non-surgery)
0.37, (surgery)
0.47, (non-surgery)
168.3 ** ± 80.2, (surgery)
164.1 ** ± 82.5,
(non-surgery)
0.48, (surgery)
0.50, (non-surgery)
[20] 20 202 ** Range 45–408 153 ** Range 42–422
[21] 54 Present in all specimens n.a. *** n.a. *** n.a. ***
[22] 40 Heavy infiltration n.a. *** Heavy infiltration n.a. ***
* CV is defined as the ratio of the standard deviation to the mean; ** Cell count per field; *** n.a is not applicable.
4. Myeloid-Derived Suppressor Cells
Myeloid cells are abundantly present in stroma of MPM [8]. MDSCs are immature myeloid
cells with immune suppressive capacities. MDSCs are generally characterized by being positive for
CD33 and CD11b and low or negative for HLA-DR. They induce Tregs and produce nitric oxide and
arginase, leading to loss of function of CD4+ and CD8+ T cells. These strongly immunosuppressive
characteristics promote immune escape, tumor growth, invasion and angiogenesis [8,18]. Immune
suppression by MDSCs was found to be one of the main factors for immunotherapy insufficiency [10].
MDSCs are induced by several tumor-derived factors, e.g., prostaglandins. Celecoxib reduces
prostaglandin levels. Veltman et al. found celecoxib to improve dendritic cell-based immunotherapy
by reducing numbers of MDSCs and suppressing function [10]. In mice, MDSCs are defined by IL-4Rα
expression [23]. Burt et al. found IL-4Rα to be highly expressed on tumor cells of 52 MPM specimens,
with presence of IL-4Rα in 97% of epithelial and 95% of non-epithelial tumors. Only a scattered and
small fraction of stromal cells stained positive for IL-4Rα, conversely macrophages were predominantly
found in stroma [24]. In another study of Burt et al., flow cytometry was performed on mononuclear
cell suspensions from seven MPM patients; these macrophages displayed high levels of IL-4Rα [18].
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Awad et al. found myeloid cells (CD33) to represent approximately 42% of CD45+ immune cells (range
5.7–86.1%); 0.6–31% of these myeloid cells were typed as MDSCs [25].
5. T Cells and Natural Killer Cells in Mesothelioma
TILs play an important role in the immune defense in cancer. They recognize tumor-specific
antigens presented on HLA-1, to then kill the tumor cells via production of perforins and granzymes.
In many cancers, T cell infiltration is associated with a good prognosis [26–28]. T helper CD4+ cells play
an important role in the generation of a T cell-mediated antitumor response, via stimulation of CD8+
TILs and NK cells and via activation of antigen-presenting cells (APCs) [29–31]. NK cells are lymphoid
cells of the innate immune system with strong immunostimulatory effector functions and efficient
cytotoxic capacity [32]. In 1982, Leigh et al. were the first to describe a relation between presence of
significant lymphoid infiltration and prolonged survival in 58 mesothelioma patients. Tumors were
found without, with insignificant and with significant lymphocyte inflammation. Due to absence of
modern immunohistochemical agents, no lymphocyte subsets could be identified [33]. Mudhar et al.
performed immunohistochemical staining on fifteen cases of epithelioid MPM, scoring CD45, CD3,
CD20 and CD56 with 0 (no significant infiltrate), 1 (non-brisk) or 2 (brisk infiltrate). In one patient,
none of these immune cells were present. Specimens demonstrated some heterogeneity in numbers of
T lymphocyte and NK cells. With brisk infiltration of T-lymphocytes and NK cells in one case, non-brisk
infiltration in eleven and ten cases, respectively. The other three and four specimens showed absence
of T lymphocytes and NK cells, respectively. No B cells were present in any specimens. No relation
was found between the infiltration of immune cells and survival [34]. A comprehensive analysis by
Hegmans et al. demonstrated leukocyte infiltration in all four MPM patients. Most inflammatory cells
were identified as macrophages and NK cells (CD16). Some heterogeneity was noted. Eosinophils,
mast cells, B cells and neutrophils were rarely detected. DCs were not found in the biopsies [35].
Immunohistochemical analysis of T cells of 32 extrapleural pneumonectomy specimens after induction
chemotherapy was performed by Anraku et al. Results are summarized in Table 3. The distribution of
T cells varies, with only CD3+ and CD45RO+ TILs showing normal distribution. The coefficient of
variation ranges from 0.49 to 0.87, implying substantial heterogeneity. In multivariate data analyses,
presence of CD8+ TILs was associated with better prognosis [36].
Table 3. Infiltration of T cell subtypes in 32 extrapeural pneumonectomy specimens.
Surface Marker Mean (Cell Count per Field) Standard Deviation Coefficient of Variation (CV) *
CD3+ 232.16 114.1 0.49
CD4+ 119.9 94.2 0.79
CD8+ 73.1 40.2 0.55
CD25+ 17.5 12.6 0.72
FOXP3+ 21.8 19.0 0.87
CD45RO+ 115.7 56.2 0.49
* CV is defined as the ratio of the standard deviation to the mean.
Yamada et al. [37] analyzed presence of TILs and NK cells in 44 MPM cases, comprised of
26 epithelioid, fourteen biphasic and four sarcomatoid mesotheliomas. Results of T cell subtype
counts are presented in Table 4. Again, the heterogeneity is substantial, indicated by wide ranges
and CVs ranging from 0.82 to 1.54. Presence of CD4+ and CD8+ T cells was strongly correlated
(R = 0.74, and p = 0.001). In multivariate data analysis high CD8+ TILs and epithelioid histology were
independent favorable prognostic factors [37].
Awad et al. [25] performed flow cytometry with various leukocyte markers on 38 malignant
mesothelioma, with all histologies. They found considerable variability in immune cell infiltration
across tumors. Numbers of CD45+ leukocytes were increased in non-epithelioid mesothelioma
compared to epithelioid mesothelioma (median 91.4% vs. 64.1%). Amount of T cells ranged from
5.2% to 81.2% of CD45+ cells, with a higher fraction of T cells in non-epithelioid mesothelioma.
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There was considerable variability in numbers of leukocytes and in immune cell composition across
cases [25]. Marcq et al. [21] found lymphocytic infiltration in all 54 tested mesotheliomas, ranging
from 20% to 80% of stromal cells. The fourteen chemotherapy pretreated samples showed higher
numbers of lymphocytes. CD8+ TILs were the predominant cell type of the immune infiltrate and were
present in all samples. In 70% of the untreated and 57% of the pretreated samples, the majority of the
lymphocytes were CD8+ TILs. High expression of CD45RO on stromal lymphocytes was associated
with worse response to chemotherapy. T helper cells were found in 85% of untreated and 100% of
pretreated samples. T helper cells in lymphoid infiltrates were associated with better survival in
multivariate analysis [21]. Suzuki et al. [38] evaluated inflammatory responses in tumor and stroma of
175 chemotherapy naive epithelioid MPM specimens with H&E-stained slides. Acute response was
represented by presence of neutrophils, while chronic inflammation was represented by lymphocytes
and plasma cells. Acute inflammatory reaction was sparse in tumors and stroma, with high scores
(>1% of total area) in 18% of specimens. The chronic reaction was more heterogenic, with high scores
(>50% of total area) in 37% of tumors and 34% of stromal tissue. In multivariate analysis, chronic
inflammation in stroma was an independent predictor of survival while other inflammatory responses
were not significantly correlated with survival [38]. These studies suggest considerable infiltration of
TILs in mesothelioma. Higher levels of TILs are associated with better survival in most studies.
Table 4. Infiltration of T cell subtypes in 44 MPM cases [37].
Surface Marker Mean (Cell Count per Field) Standard Deviation Coefficient of Variation (CV) * Range Median
CD4+ 51.1 41.8 0.82 0.2–159.7 37.3
CD8+ 103.3 106.9 1.03 8.8–547.5 64.5
CD56+ 5.4 8.3 1.54 0.0–41.8 1.8
* CV is defined as the ratio of the standard deviation to the mean.
6. Regulatory T Cells (Tregs)
FOXP3+CD25+CD4+ regulatory T cells maintain self-tolerance and prevent autoimmune disease.
They are abundantly present in tumors, where they suppress activation and proliferation of effector T
cells. High numbers of Tregs are associated with poor prognosis in many cancers [39]. Hegmans et al.
demonstrated that human mesothelioma biopsies harbor significant numbers of Tregs at the rim of
the tumor [35]. Marcq et al. [21] found Tregs to be present in 72% of samples, both chemotherapy
pretreated and untreated. Lower numbers of Tregs were seen in samples pretreated with cisplatin
and pemetrexed [21]. DeLong et al. performed flow cytometry on malignant pleural effusions from
seven patients with mesothelioma; 7.8% ± 6.8% of T-lymphocytes were functionally suppressive
CD4+CD25+ cells, which might be Tregs. This is a significant lower number of Tregs than seen in
malignant effusions secondary to breast cancer or NSCLC. Some heterogeneity was noted, including
two patients with <3% CD4+CD25+ T cells and one patient with 21% CD4+CD25+ T cells in pleural
effusion. The latter was a sarcomatoid subtype [40].
7. B Lymphocytes
B lymphocytes contribute to humoral immunity as they can differentiate into antibody-secreting
plasma cells. Also, B cells can stimulate T cells or serve as APCs. In several cancers, including
mesothelioma, B lymphocyte infiltration is associated with better patient survival [41]. Two studies
found low numbers of B lymphocytes (CD20) in mesothelioma [34,35]. A third study found low
B lymphocyte (CD19) infiltration (median 3% of CD45+ cells), although some outliers with B cell
infiltration up to 51.8% of CD45+ cells were seen [26]. Patil et al. [42] classified three molecular
subgroups based on immune profiles; in one subgroup high numbers of B cells were found [42].
Generally, B cell infiltration in mesothelioma is sparse, although a subgroup with higher numbers of B
cells is described. More research is needed for determining the clinical implications.
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8. Cancer-Associated Fibroblasts (CAFs)
The major component of the TME are cancer-associated fibroblasts, also known as
tumor-associated fibroblasts [43]. MPM recruit and activate CAFs by secreting fibroblast growth
factor-2 (FGF-2) and platelet-derived growth factor-AA (PDGF-AA) [44]. CAFs can contribute to tumor
growth by inhibiting cytotoxic T cell influx and by secreting several growth factors such as hepatocyte
growth factor, thereby inducing angiogenesis [44,45]. In 1996 Harvey et al. demonstrated infiltration
of CAFs in six of eight MPM samples [46]. Li et al. performed histological analyses on specimens from
51 MPM patients and revealed considerable CAF infiltration [44].
9. PD-L1 Expression and Other Immune Checkpoints
Programmed cell death 1 (PD-1) is an immune checkpoint receptor present on activated
T cells. PD-1 and its ligands, PD-L1 and PD-L2, which are expressed by tumor cells and/or
stromal cells share immunosuppressive capacities [47]. In several tumors, including NSCLC, PD-L1
enrichment is associated with higher response rates to PD-1 and PD-L1-blocking antibodies [47–49].
However, responses have also been observed in PD-L1-negative patients [50]. We found eight
studies evaluating PD-L1 expression in mesothelioma. A summary of the results is displayed in
Table 5. PD-L1 was found to be expressed in 16% to 65% of malignant mesothelioma. PD-L1
expression is higher in non-epithelioid mesothelioma compared to epithelioid mesothelioma
(37.5–97.4% vs. 6.7–31%) [21,25,42,50–54]. Several studies found higher PD-L1 expression to be an
independent prognostic indicator for worse overall survival in multivariate data analysis [50,52,53,55].
Khanna et al. [54] analyzed PD-L1 expression in peritoneal and pleural fluid of respectively six and
three mesothelioma patients. PD-L1 expression was found in all samples, varying from 12% to 83%.
Immune cells were evaluated for PD-1 expression in seven samples. PD-1 was expressed in 21.8%
of CD4+ cells and 37.5% of CD8+ cells. Together, these data suggest that malignant effusions of
mesothelioma patients have high PD-L1 expression on tumor cells as well as PD-L1 and PD-1 on
infiltrating immune cells [54]. Staining for other checkpoint inhibitors such as TIM-3 and LAG-3
was performed by Marcq et al. [21] TIM-3 expression was found in 36 of 54 samples (both treated
and untreated). LAG-3 expression was absent in all 54 MPM samples, pointing out the possible
opportunities of TIM-3 as a promising immunotherapy target in mesothelioma. In multivariate
analysis, TIM-3 expression in lymphoid aggregates was a prognosticator for better survival [21].
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Table 5. PD-L1 expression in mesothelioma.
Study PD-L1Antibody n Positivity (%)
PD-L1 Positive
(n (%))
PD-L1 Positive in
Epithelioid (n (%))
PD-L1 Positive in
Non-Epithelioid (n (%))
Survival in PD-L1+
(Months)
Survival in PD-L1-
(Months) p Value
[53] 5H1-A3 106 ≥5 42 (40) 14/68 (21) 37/38 (97) 5 14.5 <0.0001
[51] E1L3N 77 >1% 16 (21) 7/53 (13) 9/24 (38) 4.8 16.3 0.012
[26] E1L3N 39 ≥1% 18 (46) 8/26 (31) 10/13 (77) shorter longer 0.15
[50] E1L3N 58 ≥1% 17 (29) 8/34 (24) 9/24 (38) n.a.* n.a.* n.a.*
[50] SP142 58 ≥1% 10 (17) 4/34 (12) 6/24 (25) 4 13 0.016
[54] rabbit 65 ≥5% 41 (63) n.a.* n.a.* 23.0 33.3 0.35
[21] SP142 54 ≥1% 35 (65) n.a.* More in sarcomatoid n.a.* n.a.* n.a.*
[52] E1L3N 175 ≥5% 57 (33) 46/148 (31) 11/27 (41) 6 18 <0.01
[42] SP142 99 >1% 16 (16) 5/75 (6.7) 9/24 (38) shorter longer
* n.a is not applicable.
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10. Discussion
We performed a comprehensive literature search focusing on the heterogeneity of immune cell
infiltration, PD-L1 expression and other immune checkpoints in MPM. The composition of TME holds
therapeutic and prognostic implications [6,7]. Stage and histology are currently accepted prognostic
indicators [5], but evidence is accumulation that infiltrating immune cells and expression of immune
checkpoints are of high prognostic value in MPM [7,50–53]. Infiltration of M2 macrophages seems to
be associated with worse prognoses [18–20], as is PD-L1 expression [50–53]. Infiltration of cytotoxic T
cells was associated with better prognosis in MPM in most studies [21,33,36–38].
TME composition differs between various histologic subtypes and individuals [25]. Macrophages
are found to be abundantly present in all MPM, although the level of infiltration can vary significantly.
Macrophages generally show an M2 phenotype [18–22,24]. Stroma of MPM is infiltrated by
MDSCs [8,18,25]. Leukocyte infiltration was found in almost all mesothelioma, with higher numbers
of leukocytes in non-epithelioid mesothelioma [25]. T cell subsets showed considerable heterogeneity
with wide ranges and high coefficients of variation across all studies. Cytotoxic T cells, NK cells and T
helper cells were most abundantly present [21,33–38]. B cell infiltration is sparse, although a (molecular)
subgroup with an increased number B cells is described [25,34,35,42]. Significant numbers of Tregs
were found in biopsies and pleural fluid of mesothelioma [21,35,40]. Tumor growth promoting CAFS
are found in TME of most MPM [44,46]. PD-L1 expression is commonly found in MPM, with higher
expression in non-epithelioid histologic subtypes [21,25,42,50–54].
Altogether, substantial heterogeneity in immune cell content in mesothelioma was found. MPM
are highly infiltrated by immune effector cells, but also immune suppressive cells such as Tregs and
M2 macrophages and PD-L1 expression are found. Apparently, the tumor finds several ways to
bypass the immune system. Thoroughly mapping the composition of the TME is rational in targeting
therapy in mesothelioma. For example, tumors with high amounts of T effector cells and Tregs
might benefit from a combination of immunotherapy and drugs that control Tregs, to invigorate
immunotherapy efficacy. Tumors highly infiltrated by MDSCs might benefit more from (dendritic
cell-based) immunotherapy when this is combined with celecoxib, as this reduces the suppressive
function and number of MDSCs [10]. In MPM expressing PD-L1 and cytotoxic T cells present in TME,
treatment with PD-(L)1 inhibitors is more rational. Other rational treatment options include nintedanib
or emactuzumab for the skewing of M2 macrophages to the M1 subtype in TME highly infiltrated with
M2 macrophages [16,17], or OX40 for the stimulation of cytotoxic T cells when they are not already
present in the TME [56]. Inhibition of the cytokines FGF-2, PDGF-AA, and HGF may be appropriate in
MPM infiltrated with CAFs [44]. This opens up a whole new era of personalized immunotherapy in
which we are just scratching the surface. Researchers should be aware of the extensive possibilities that
exist for a tumor to evade the cytotoxic killing by the immune system. Therefore, no “one size fits all”
treatment is likely to be found and focus should lie on the heterogeneity of the tumors and TME.
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